265 related articles for article (PubMed ID: 21269503)
1. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
Tseng CL; Oxlade O; Menzies D; Aspler A; Schwartzman K
BMC Public Health; 2011 Jan; 11():55. PubMed ID: 21269503
[TBL] [Abstract][Full Text] [Related]
2. Potential cost-effectiveness of a new infant tuberculosis vaccine in South Africa--implications for clinical trials: a decision analysis.
Ditkowsky JB; Schwartzman K
PLoS One; 2014; 9(1):e83526. PubMed ID: 24454706
[TBL] [Abstract][Full Text] [Related]
3. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
4. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
[TBL] [Abstract][Full Text] [Related]
6. The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality.
Harris RC; Dodd PJ; White RG
BMC Med; 2016 Sep; 14(1):138. PubMed ID: 27633883
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of universal BCG vaccination of Japanese infants.
Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
[TBL] [Abstract][Full Text] [Related]
9. Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland.
Sweeney E; Dahly D; Seddiq N; Corcoran G; Horgan M; Sadlier C
BMC Infect Dis; 2019 May; 19(1):397. PubMed ID: 31072396
[TBL] [Abstract][Full Text] [Related]
10. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.
Mangtani P; Nguipdop-Djomo P; Keogh RH; Trinder L; Smith PG; Fine PE; Sterne J; Abubakar I; Vynnycky E; Watson J; Elliman D; Lipman M; Rodrigues LC
Health Technol Assess; 2017 Jul; 21(39):1-54. PubMed ID: 28738015
[TBL] [Abstract][Full Text] [Related]
11. The long-term health and economic benefits of DOTS implementation in Ecuador.
Oxlade O; Vaca J; Romero E; Schwartzman K; Graham B; Hernandez L; Tannenbaum T; Menzies D
Can J Public Health; 2006; 97(1):14-9. PubMed ID: 16512320
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis vaccine: A journey from BCG to present.
Fatima S; Kumari A; Das G; Dwivedi VP
Life Sci; 2020 Jul; 252():117594. PubMed ID: 32305522
[TBL] [Abstract][Full Text] [Related]
13. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
[TBL] [Abstract][Full Text] [Related]
14. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
[TBL] [Abstract][Full Text] [Related]
15. NATCON 2022 Panel discussion: "TB vaccination - Going Forward".
Banurekha VV; Padmapriyadarsini C; Bhargava S; Sachdeva K
Indian J Tuberc; 2023 Jul; 70(3):366-369. PubMed ID: 37562914
[TBL] [Abstract][Full Text] [Related]
16. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Tameris M; Geldenhuys H; Luabeya AK; Smit E; Hughes JE; Vermaak S; Hanekom WA; Hatherill M; Mahomed H; McShane H; Scriba TJ
PLoS One; 2014; 9(2):e87340. PubMed ID: 24498312
[TBL] [Abstract][Full Text] [Related]
17. What's Old and New in Tuberculosis Vaccines for Children.
Cranmer LM; Cotton MF; Day CL; Nemes E
J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S110-S116. PubMed ID: 36314550
[TBL] [Abstract][Full Text] [Related]
18. Tuberculosis vaccine.
Sarhan MA
Saudi Med J; 2010 Jan; 31(1):9-13. PubMed ID: 20062891
[TBL] [Abstract][Full Text] [Related]
19. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
